As the US FDA’s efforts to inspect data integrity into pharmaceutical manufacturing begin showing results, the agency is finding more problems with out-of-specification investigations, the agency’s Carmelo Rosa told the recent International Society for Pharmaceutical Engineering annual meeting in Philadelphia.
Rosa assured the audience that there’s much work left to do on data integrity, and not just in connection with analytical laboratories. “People often think that data integrity is only about the laboratory system,” Rosa said